1.77
Tela Bio Inc stock is traded at $1.77, with a volume of 97,402.
It is up +2.91% in the last 24 hours and down -7.33% over the past month.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
See More
Previous Close:
$1.72
Open:
$1.68
24h Volume:
97,402
Relative Volume:
0.85
Market Cap:
$70.12M
Revenue:
$63.15M
Net Income/Loss:
$-40.30M
P/E Ratio:
-1.0599
EPS:
-1.67
Net Cash Flow:
$-44.47M
1W Performance:
+12.03%
1M Performance:
-7.33%
6M Performance:
-34.93%
1Y Performance:
-38.54%
Tela Bio Inc Stock (TELA) Company Profile
Name
Tela Bio Inc
Sector
Industry
Phone
484-320-2930
Address
1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA
Compare TELA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TELA
Tela Bio Inc
|
1.77 | 67.35M | 63.15M | -40.30M | -44.47M | -1.67 |
![]()
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
![]()
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
![]()
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Tela Bio Inc Stock (TELA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
May-31-22 | Initiated | Lake Street | Buy |
Dec-03-19 | Initiated | Canaccord Genuity | Buy |
Dec-03-19 | Initiated | JMP Securities | Mkt Outperform |
Dec-03-19 | Initiated | Jefferies | Buy |
Dec-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Tela Bio Inc Stock (TELA) Latest News
TELA Bio Posts Double-Digit Revenue Growth, Expands Product Reach in Q2 - MSN
Leading vs lagging indicators on TELA Bio Inc. performance2025 Trade Ideas & Reliable Intraday Trade Alerts - Newser
How TELA Bio Inc. stock performs during market volatilityQuarterly Portfolio Summary & Technical Entry and Exit Alerts - thegnnews.com
How to use Fibonacci retracement on TELA Bio Inc.2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is TELA Bio Inc. forming a bottoming baseJuly 2025 PreEarnings & Capital Efficient Trade Techniques - Newser
Can trapped investors hope for a rebound in TELA Bio Inc.Quarterly Portfolio Review & Reliable Volume Spike Trade Alerts - Newser
Using flow based indicators on TELA Bio Inc.Portfolio Return Report & Growth-Oriented Investment Plans - Newser
Can swing trading help recover from TELA Bio Inc. lossesCPI Data & Stock Portfolio Risk Management - Newser
Resistance Break Could Fuel TELA Bio Inc. RallyQuarterly Portfolio Summary & Weekly Stock Performance Updates - beatles.ru
TELA Bio Inc. stock trend forecastJuly 2025 Earnings & Capital Efficiency Focused Ideas - Newser
TELA Bio Awards Inducement Equity Grants to New Employees - MSN
TELA Bio’s SWOT analysis: biologic innovator’s stock faces growth hurdles - Investing.com India
Investors Give TELA Bio, Inc. (NASDAQ:TELA) Shares A 27% Hiding - 富途牛牛
Insider Traders Lose US$143k As TELA Bio Drops - simplywall.st
Tools to assess TELA Bio Inc.’s risk profileJuly 2025 Update & Verified Momentum Watchlists - Newser
TELA Bio’s SWOT analysis: biologic innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Tela Bio at Canaccord Conference: Strategic Growth in Soft Tissue Repair - Investing.com Canada
Tela Bio shares fall 2.50% premarket after announcing inducement grants to new employees. - AInvest
Tela Bio reiterates $85M–$88M 2025 revenue target as international expansion accelerates - MSN
Will TELA Bio Inc. stock benefit from AI tech trendsSwing Entry Risk Mitigation with Chart Analysis - Newser
Tela Bio shares fall 6.88% after-hours following inducement grants to new employees. - AInvest
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 - MarketScreener
TELA Bio (TELA) Gets a Buy from Lake Street - The Globe and Mail
TELA Bio 2025 Q2 Earnings Net Loss Narrows Amid Revenue Growth - AInvest
TELA Bio Reports Strong Q2 2025 Financial Results - MSN
TELA Bio Inc (TELA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... - Yahoo Finance
TELA Bio Inc (TELA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... By GuruFocus - Investing.com Canada
TELA Bio Reports Strong Q2 2025 Growth - TipRanks
TELA Bio Reports Second Quarter 2025 Financial Results - GlobeNewswire
TR | OpenAI4o Maintains TELA Bio(TELA.US) With Hold Rating, Maintains Target Price $2 - 富途牛牛
TELA Bio’s Revenue Climbed But Fell Short Of Expectations - Finimize
Contradictions Unveiled: TELA Bio's Q2 2025 Earnings Call Highlights Shifts in Sales Strategy, Product Growth, and Pricing Positioning - AInvest
Tela Bio (TELA): A Compelling Post-Earnings Case for Long-Term Value Creation in a High-Growth MedTech Sector - AInvest
Tela Bio's 2025 Revenue Guidance and Global Expansion: A Strategic Inflection Point for Scalable Growth - AInvest
Tela Bio Exceeds $20M Revenue in Q2 2025, Reiterates $85M-$88M 2025 Target Amid International Expansion - AInvest
Earnings call transcript: Tela Bio Q2 2025 sees stock rise despite EPS miss - Investing.com Canada
Earnings call transcript: Tela Bio Q2 2025 sees stock rise despite EPS miss By Investing.com - Investing.com South Africa
Tela Bio earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Tela Bio reports Q2 EPS (22c), consensus (19c) - TipRanks
Intraday pattern recognizer results for TELA Bio Inc.Daily Stock Watch Summary with Key Insights - Newser
TELA Bio's Q2 Revenue Miss: A Crossroads of Short-Term Pressures and Long-Term R&D Promise in Biotech - AInvest
TELA Bio misses Q2 revenue estimates - MarketScreener
Tela Bio Inc Stock (TELA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tela Bio Inc Stock (TELA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Talmo Paul | Chief Technology Officer |
Oct 24 '24 |
Buy |
2.25 |
22,222 |
50,000 |
91,082 |
KOBLISH ANTONY | Chief Executive Officer |
Oct 24 '24 |
Buy |
2.25 |
88,888 |
199,998 |
458,897 |
Firestone Gregory A. | Chief Commercial Officer |
Oct 24 '24 |
Buy |
2.25 |
6,666 |
14,998 |
57,279 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):